Results for tag: "DPP IV Inhibitor"

DPP IV inhibitors are a class of drugs used to treat type 2 diabetes. They work by blocking the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the hormone incretin. This helps to increase the amount of incretin in the body, which in turn helps to reduce blood sugar levels. DPP IV inhibitors are usually taken in combination with other diabetes drugs, such as metformin, sulfonylureas, or thiazolidinediones. They are generally well tolerated and have few side effects. The DPP IV inhibitor market is a growing segment of the diabetes drug market. It is expected to continue to grow as more people are diagnosed with type 2 diabetes and the need for effective treatments increases. The market is highly competitive, with many companies offering different types of DPP IV inhibitors. Some of the major players in the market include Novo Nordisk, Merck, Sanofi, Eli Lilly, and Boehringer Ingelheim. Show Less Read more